Sections
| Title | Starting Page | Number of Pages |
|---|
| 1 Table of Contents | 3 | 5 |
| 1.1 List of Tables | 6 | 1 |
| 1.2 List of Figures | 6 | 2 |
| 2 Introduction | 8 | 1 |
| 2.1 GBI Research Report Guidance | 8 | 1 |
| 3 The Future of the Pharmaceutical Packaging Industry Industry Overview | 9 | 5 |
| 3.1 Introduction | 9 | 1 |
| 3.1.1 Key Aspects of Packaging | 10 | 1 |
| 3.2 Industry Segments in Pharmaceutical Packaging | 11 | 1 |
| 3.2.1 Blister Packaging | 12 | 1 |
| 3.2.2 Plastic Bottles | 12 | 1 |
| 3.2.3 Labels and Accessories | 12 | 1 |
| 3.2.4 Drug Delivery Devices | 12 | 1 |
| 3.2.5 Pouches and Strip Packs | 13 | 1 |
| 3.2.6 Caps and Closures | 13 | 1 |
| 3.2.7 Secondary Containers | 13 | 1 |
| 3.2.8 Others | 13 | 1 |
| 4 The Future of the Pharmaceutical Packaging Industry Market Characterization | 14 | 3 |
| 4.1 Market Forecasts | 14 | 3 |
| 5 The Future of the Pharmaceutical Packaging Industry Market Drivers, Challenges and Key Trends | 17 | 9 |
| Growth Drivers | 17 | 1 |
| 5.1.1 Emerging Countries Show Immense Growth Potential for Global Pharmaceutical Industry | 17 | 1 |
| 5.1.2 Increasing Usage of Biologics Will Require Innovative Packaging Solutions | 18 | 1 |
| 5.1.3 Ageing Population Will Drive Demand for Pharmaceutical Products | 19 | 1 |
| 5.1.4 Patent Expiries of Prescription Drugs Will Boost the Usage of Generics | 19 | 1 |
| 5.2 Market Challenges | 20 | 1 |
| 5.2.1 Producing Consistent Quality in the Market is a Challenge for Pharmaceutical Packaging Supplier | 20 | 1 |
| 5.2.2 Availability and Price Volatility of Raw Materials is a Conundrum for Pharmaceutical Packaging Companies | 21 | 1 |
| Changes in Health Safety Regulations Are Frequent and Have Serious Effects on Sales of Pharmaceutical Packaging Suppliers | 21 | 1 |
| 5.3 Key Industry Trends | 22 | 1 |
| 5.3.1 Changes in Procurement Strategy will Drive Value across the Business Due to the Impact of Recession | 22 | 1 |
| 5.3.2 Quality is the Critical Success Factor for Selecting a Packaging Supplier | 23 | 1 |
| 5.3.3 Spending On Pharmaceutical Packaging Is Expected To Increase over the Next 12 Months | 23 | 2 |
| 5.3.4 Review Pricing as a Business Opportunity is the Most Preferred Strategy | 25 | 1 |
| 6 The Future of the Pharmaceutical Packaging Industry Geographic Landscape | 26 | 9 |
| 6.1 Geographical Split | 26 | 1 |
| 6.2 Geographical Trends | 27 | 1 |
| 6.2.1 Pharmaceutical Packaging in APAC Region will Grow Faster than the US and Europe | 27 | 1 |
| 6.2.2 Growth in the Packaging Industry in Emerging Nations Will be Faster than the Developed Nations | 27 | 1 |
| 6.3 Emerging Markets | 28 | 1 |
| 6.3.1 China | 28 | 1 |
| 6.3.1.1 Overview | 28 | 1 |
| 6.3.1.2 Porter s Diamond | 29 | 1 |
| 6.3.1.3 Trends | 30 | 1 |
| 6.3.2 India | 30 | 1 |
| 6.3.2.1 Overview | 30 | 1 |
| 6.3.2.2 Porter s Diamond | 30 | 1 |
| 6.3.2.3 Trends | 31 | 1 |
| 6.3.3 Brazil | 31 | 1 |
| 6.3.3.1 Overview | 31 | 1 |
| 6.3.3.2 Porter s Diamond | 32 | 1 |
| 6.3.3.3 Trends | 33 | 1 |
| 6.3.4 Russia | 33 | 1 |
| 6.3.4.1 Overview | 33 | 1 |
| 6.3.4.2 Porter s Diamond | 33 | 1 |
| 6.3.4.3 Trends | 34 | 1 |
| 7 The Future of the Pharmaceutical Packaging Industry Regulatory Framework | 35 | 4 |
| 7.1 International Standards for Pharmaceutical Packaging | 35 | 1 |
| 7.1.1 PS 9000:2001 - Pharmaceutical Packaging Materials | 35 | 1 |
| 7.1.2 ISO 15378: 2006 | 35 | 1 |
| 7.2 National Guidelines for Pharmaceutical Packaging | 36 | 1 |
| 7.2.1 Regulatory Framework in the US | 37 | 1 |
| 7.2.1.1 Guideline on Container Closure Systems | 37 | 1 |
| 7.2.1.2 US Pharmacopeia | 37 | 1 |
| 7.2.1.3 Guideline on RFID and Changes in Packaging Material | 37 | 1 |
| 7.2.2 Regulatory Framework in Europe | 37 | 1 |
| 7.2.2.1 EMEA Good Manufacturing Practices | 37 | 1 |
| 7.2.2.2 EMEA Quality Guidelines (Volume 3) | 37 | 1 |
| 7.2.2.3 EMEA Regulatory Guidelines (Volume 2B) | 37 | 1 |
| 7.2.2.4 European Pharmacopoeia | 38 | 1 |
| 7.2.3 Regulatory Framework in Asia Pacific | 38 | 1 |
| 7.2.3.1 Overview | 38 | 1 |
| 8 The Future of the Pharmaceutical Packaging Industry Competitive Landscape | 39 | 20 |
| 8.1 Rexam | 39 | 1 |
| 8.1.1 Business Description | 39 | 1 |
| 8.1.2 Financial Performance | 40 | 1 |
| 8.1.3 Deals and Alliances | 40 | 1 |
| 8.2 Schott | 41 | 1 |
| 8.2.1 Business Description | 41 | 1 |
| 8.2.2 Financial Performance | 42 | 1 |
| 8.2.3 Deals and Alliances | 42 | 1 |
| 8.3 Alcan Packaging | 43 | 1 |
| 8.3.1 Business Description | 43 | 1 |
| 8.3.2 Deals and Alliances | 44 | 1 |
| 8.4 Nypro | 44 | 1 |
| 8.4.1 Business Description | 45 | 1 |
| 8.4.2 Financial Performance | 45 | 1 |
| 8.5 Consort Medical | 46 | 1 |
| 8.5.1 Business Description | 46 | 1 |
| 8.5.2 Financial Performance | 47 | 1 |
| 8.6 Becton Dickinson | 47 | 1 |
| 8.6.1 Business Description | 47 | 1 |
| 8.6.2 Financial Performance | 48 | 1 |
| 8.6.3 Deals and Alliances | 48 | 1 |
| 8.7 Gerresheimer | 49 | 1 |
| 8.7.1 Business Description | 49 | 1 |
| 8.7.2 Financial Performance | 50 | 1 |
| 8.7.3 Deals and Alliances | 50 | 1 |
| 8.8 West Pharmaceutical Services | 50 | 1 |
| 8.8.1 Business Description | 51 | 1 |
| 8.8.2 Financial Performance | 51 | 1 |
| 8.8.3 Deals and Alliances | 51 | 1 |
| 8.9 AMCOR | 52 | 1 |
| 8.9.1 Business Description | 52 | 1 |
| 8.9.2 Financial Performance | 53 | 1 |
| 8.10 Ypsomed | 53 | 1 |
| 8.10.1 Business Description | 53 | 1 |
| 8.10.2 Financial Performance | 54 | 1 |
| 8.11 Bormioli Rocco | 54 | 1 |
| 8.11.1 Business Description | 54 | 1 |
| 8.12 Duran | 55 | 1 |
| 8.12.1 Business Description | 55 | 1 |
| 8.13 Catalent | 56 | 1 |
| 8.13.1 Business Description | 57 | 1 |
| 8.13.2 Deals and Alliances | 57 | 1 |
| 8.14 Meadwestvaco | 58 | 1 |
| 8.14.1 Business Description | 58 | 1 |
| 9 The Future of the Pharmaceutical Packaging Industry Strategic Consolidations | 59 | 1 |
| 9.1 Overview | 59 | 1 |
| 9.2 Schott AG and Medical Glass S.A., DIESCA S.A. | 59 | 1 |
| 9.3 Gerresheimer and EDP | 59 | 1 |
| 9.4 Bilcare/ Meadwestvaco Corp and International Labs | 59 | 1 |
| 9.5 Alcan Packaging and Associated Capsules Private Limited | 59 | 1 |
| 10 The Future of the Pharmaceutical Packaging Industry Appendix | 60 | 3 |
| 10.1 Market Definitions | 60 | 1 |
| 10.2 Abbreviations | 60 | 1 |
| 10.3 Research Methodology | 60 | 3 |
| 10.3.1 Coverage | 61 | 1 |
| 10.3.2 Secondary Research | 61 | 1 |
| 10.3.3 Primary Research | 61 | 1 |
| 10.3.4 Expert Panel Validation | 62 | 1 |
| 10.4 Contact Us | 62 | 1 |
| 10.5 Disclaimer | 62 | 1 |
| 10.6 Sources | 62 | 1 |